Pinpointing the tumor-specific T-cells via TCR clusters

  1. Mikhail M Goncharov
  2. Ekaterina A Bryushkova
  3. Nikita I Sharayev
  4. Valeria D Skatova
  5. Anastasiya M Baryshnikova
  6. George V Sharonov
  7. Vadim Karnaukhov
  8. Maria T Vakhitova
  9. Igor V Samoylenko
  10. Lev V Demidov
  11. Sergey Lukyanov
  12. Dmitriy M Chudakov  Is a corresponding author
  13. Ekaterina O Serebrovskaya
  1. Skolkovo Institute of Science and Technology, Russian Federation
  2. Pirogov Russian National Research Medical University, Russian Federation
  3. Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Federation
  4. NN Blokhin Russian Cancer Research Center, Russian Federation

Abstract

Adoptive T cell transfer (ACT) is a promising approach to cancer immunotherapy, but its efficiency fundamentally depends on the extent of tumor-specific T-cell enrichment within the graft. This can be estimated via activation with identifiable neoantigens, tumor-associated antigens (TAAs), or living or lyzed tumor cells, but these approaches remain laborious, time-consuming, and functionally limited, hampering clinical development of ACT. Here, we demonstrate that homology cluster analysis of T cell receptor (TCR) repertoires efficiently identifies tumor-reactive TCRs allowing to: 1) detect their presence within the pool of tumor-infiltrating lymphocytes (TILs); 2) optimize TIL culturing conditions, with IL-2low/IL-21/anti-PD-1 combination showing increased efficiency; 3) investigate surface marker-based enrichment for tumor-targeting T cells in freshly-isolated TILs (enrichment confirmed for CD4+ and CD8+ PD-1+/CD39+ subsets), or re-stimulated TILs (informs on enrichment in 4-1BB-sorted cells). We believe that this approach to the rapid assessment of tumor-specific TCR enrichment should accelerate T cell therapy development.

Data availability

TCR repertoires have been deposited on:https://figshare.com/projects/Pinpointing_the_tumor-specific_T-cells_via_TCR_clusters/125284

Article and author information

Author details

  1. Mikhail M Goncharov

    Center of Life Sciences, Skolkovo Institute of Science and Technology, Moscow, Russian Federation
    Competing interests
    The authors declare that no competing interests exist.
  2. Ekaterina A Bryushkova

    Pirogov Russian National Research Medical University, Moscow, Russian Federation
    Competing interests
    The authors declare that no competing interests exist.
  3. Nikita I Sharayev

    Center of Life Sciences, Skolkovo Institute of Science and Technology, Moscow, Russian Federation
    Competing interests
    The authors declare that no competing interests exist.
  4. Valeria D Skatova

    Pirogov Russian National Research Medical University, Moscow, Russian Federation
    Competing interests
    The authors declare that no competing interests exist.
  5. Anastasiya M Baryshnikova

    Genomics of Adaptive Immunity Department, Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russian Federation
    Competing interests
    The authors declare that no competing interests exist.
  6. George V Sharonov

    Pirogov Russian National Research Medical University, Moscow, Russian Federation
    Competing interests
    The authors declare that no competing interests exist.
  7. Vadim Karnaukhov

    Center of Life Sciences, Skolkovo Institute of Science and Technology, Moscow, Russian Federation
    Competing interests
    The authors declare that no competing interests exist.
  8. Maria T Vakhitova

    Pirogov Russian National Research Medical University, Moscow, Russian Federation
    Competing interests
    The authors declare that no competing interests exist.
  9. Igor V Samoylenko

    Oncodermatology Department, NN Blokhin Russian Cancer Research Center, Moscow, Russian Federation
    Competing interests
    The authors declare that no competing interests exist.
  10. Lev V Demidov

    Oncodermatology Department, NN Blokhin Russian Cancer Research Center, Moscow, Russian Federation
    Competing interests
    The authors declare that no competing interests exist.
  11. Sergey Lukyanov

    Pirogov Russian National Research Medical University, Moscow, Russian Federation
    Competing interests
    The authors declare that no competing interests exist.
  12. Dmitriy M Chudakov

    Department of genomics of adaptive immunity, Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russian Federation
    For correspondence
    chudakovdm@gmail.com
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0430-790X
  13. Ekaterina O Serebrovskaya

    Pirogov Russian National Research Medical University, Moscow, Russian Federation
    Competing interests
    The authors declare that no competing interests exist.

Funding

Ministry of Science and Higher Education of the Russian Federation (075-15-2020-807)

  • Dmitriy M Chudakov

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: All clinical samples were acquired from the N.N. Blokhin National Medical Research Center of Oncology in accordance with protocol MoleMed-0921, approved by the ethical committee on 30 Jan 2020. All patients involved in the study were diagnosed with metastatic melanoma and signed an informed consent prior to collection of their biomaterial.

Copyright

© 2022, Goncharov et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,224
    views
  • 534
    downloads
  • 18
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Mikhail M Goncharov
  2. Ekaterina A Bryushkova
  3. Nikita I Sharayev
  4. Valeria D Skatova
  5. Anastasiya M Baryshnikova
  6. George V Sharonov
  7. Vadim Karnaukhov
  8. Maria T Vakhitova
  9. Igor V Samoylenko
  10. Lev V Demidov
  11. Sergey Lukyanov
  12. Dmitriy M Chudakov
  13. Ekaterina O Serebrovskaya
(2022)
Pinpointing the tumor-specific T-cells via TCR clusters
eLife 11:e77274.
https://doi.org/10.7554/eLife.77274

Share this article

https://doi.org/10.7554/eLife.77274

Further reading

    1. Immunology and Inflammation
    Alexandra a Aybar-Torres, Lennon A Saldarriaga ... Lei Jin
    Research Article

    The significance of STING1 gene in tissue inflammation and cancer immunotherapy has been increasingly recognized. Intriguingly, common human STING1 alleles R71H-G230A-R293Q (HAQ) and G230A-R293Q (AQ) are carried by ~60% of East Asians and ~40% of Africans, respectively. Here, we examine the modulatory effects of HAQ, AQ alleles on STING-associated vasculopathy with onset in infancy (SAVI), an autosomal dominant, fatal inflammatory disease caused by gain-of-function human STING1 mutations. CD4 T cellpenia is evident in SAVI patients and mouse models. Using Sting1 knock-in mice expressing common human STING1 alleles HAQ, AQ, and Q293, we found that HAQ, AQ, and Q293 splenocytes resist STING1-mediated cell death ex vivo, establishing a critical role of STING1 residue 293 in cell death. The HAQ/SAVI(N153S) and AQ/SAVI(N153S) mice did not have CD4 T cellpenia. The HAQ/SAVI(N153S), AQ/SAVI(N153S) mice have more (~10-fold, ~20-fold, respectively) T-regs than WT/SAVI(N153S) mice. Remarkably, while they have comparable TBK1, IRF3, and NFκB activation as the WT/SAVI, the AQ/SAVI mice have no tissue inflammation, regular body weight, and normal lifespan. We propose that STING1 activation promotes tissue inflammation by depleting T-regs cells in vivo. Billions of modern humans have the dominant HAQ, AQ alleles. STING1 research and STING1-targeting immunotherapy should consider STING1 heterogeneity in humans.

    1. Immunology and Inflammation
    Arijit Chakraborty, Arunava Bandyopadhaya ... Laurence G Rahme
    Research Article

    How bacterial pathogens exploit host metabolism to promote immune tolerance and persist in infected hosts remains elusive. To achieve this, we show that Pseudomonas aeruginosa (PA), a recalcitrant pathogen, utilizes the quorum sensing (QS) signal 2’-aminoacetophenone (2-AA). Here, we unveil how 2-AA-driven immune tolerization causes distinct metabolic perturbations in murine macrophages’ mitochondrial respiration and bioenergetics. We present evidence indicating that these effects stem from decreased pyruvate transport into mitochondria. This reduction is attributed to decreased expression of the mitochondrial pyruvate carrier (Mpc1), which is mediated by diminished expression and nuclear presence of its transcriptional regulator, estrogen-related nuclear receptor alpha (Esrra). Consequently, Esrra exhibits weakened binding to the Mpc1 promoter. This outcome arises from the impaired interaction between Esrra and the peroxisome proliferator-activated receptor gamma coactivator 1-alpha (Ppargc1a). Ultimately, this cascade results in diminished pyruvate influx into mitochondria and, consequently reduced ATP production in tolerized murine and human macrophages. Exogenously added ATP in infected macrophages restores the transcript levels of Mpc1 and Esrra and enhances cytokine production and intracellular bacterial clearance. Consistent with the in vitro findings, murine infection studies corroborate the 2-AA-mediated long-lasting decrease in ATP and acetyl-CoA and its association with PA persistence, further supporting this QS signaling molecule as the culprit of the host bioenergetic alterations and PA persistence. These findings unveil 2-AA as a modulator of cellular immunometabolism and reveal an unprecedented mechanism of host tolerance to infection involving the Ppargc1a/Esrra axis in its influence on Mpc1/OXPHOS-dependent energy production and PA clearance. These paradigmatic findings pave the way for developing treatments to bolster host resilience to pathogen-induced damage. Given that QS is a common characteristic of prokaryotes, it is likely that 2-AA-like molecules with similar functions may be present in other pathogens.